Patents by Inventor Xingmin Zhang

Xingmin Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240383911
    Abstract: Provided in the present application are macrocyclic azaindazole compounds of Formula (I), and the use thereof. The compounds have the effect of inhibiting the activity of multiple protein kinases, comprising, for example, HPK1, FLT3 and KDR.
    Type: Application
    Filed: September 16, 2022
    Publication date: November 21, 2024
    Applicant: BROADENBIO CO., LTD
    Inventors: Gongping DUAN, Xingmin ZHANG, Min LI
  • Publication number: 20230322789
    Abstract: Provided in the present application are a compound represented by formula (I), a pharmaceutical composition containing the compound, and the use thereof. The compound represented by formula (I) of the present application has a good effect in terms of inhibiting the activity of HPK1.
    Type: Application
    Filed: November 3, 2021
    Publication date: October 12, 2023
    Applicant: BroadenBio Co., Ltd.
    Inventors: Gongping Duan, Xingmin Zhang, Zhihua Wang, Xianglong Wei, Min Li
  • Patent number: 11584726
    Abstract: The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: February 21, 2023
    Assignee: BEIJING FORELAND PHARMA CO., LTD.
    Inventors: Qi Ji, Xingmin Zhang, Zhenjian Du, Longlong Gong, Lei Wang, Congmin Gao, Meijing Du
  • Publication number: 20230012600
    Abstract: Provided are a compound of formula (I), or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, and a use thereof. The above-mentioned compound has a very strong inhibitory effect on the FGFR4 kinase activity and the proliferative activity of Hep 3B cells with high FGFR4 expression.
    Type: Application
    Filed: October 21, 2020
    Publication date: January 19, 2023
    Applicant: BroadenBio Co., Ltd.
    Inventors: Qi Wang, Gongping Duan, Wei Hua, Xingmin Zhang
  • Publication number: 20210347745
    Abstract: The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.
    Type: Application
    Filed: June 21, 2018
    Publication date: November 11, 2021
    Applicant: Beijing Foreland Pharma Co., Ltd.
    Inventors: Qi Ji, Xingmin Zhang, Zhenjian Du, Longlong Gong, Lei Wang, Congmin Gao, Meijing Du
  • Patent number: 10646483
    Abstract: The present invention relates to the crystal form of imidazolone type compounds, and a preparation method, pharmaceutical composition and use thereof, and falls within the field of pharmaceutical compound crystals. The crystal form provided by the present invention has a good stability, comprising good stability under the three extreme conditions of high temperature, high humidity and strong illumination, and can also maintain a good stability during the tablet compressing process. The crystal form provided by the present invention has good absorption and metabolism properties in vivo, comprising the drug concentration of blood, the drug concentration-time curve AUC, the half-life period, etc. In addition, the dissolving rate of the crystal form of the present invention is improved, wherein same is beneficial for the applications thereof in preparations.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: May 12, 2020
    Assignee: Foreland Pharma Co., Ltd.
    Inventors: Qi Ji, Zhenjian Du, Xingmin Zhang, Lei Wang, Congmin Gao, Longlong Gong
  • Publication number: 20180369233
    Abstract: The present invention relates to the crystal form of imidazolone type compounds, and a preparation method, pharmaceutical composition and use thereof, and falls within the field of pharmaceutical compound crystals. The crystal form provided by the present invention has a good stability, comprising good stability under the three extreme conditions of high temperature, high humidity and strong illumination, and can also maintain a good stability during the tablet compressing process. The crystal form provided by the present invention has good absorption and metabolism properties in vivo, comprising the drug concentration of blood, the drug concentration-time curve AUC, the half-life period, etc. In addition, the dissolving rate of the crystal form of the present invention is improved, wherein same is beneficial for the applications thereof in preparations.
    Type: Application
    Filed: January 26, 2016
    Publication date: December 27, 2018
    Applicant: Foreland Pharma Co., Ltd.
    Inventors: Qi Ji, Zhenjian Du, Xingmin Zhang, Lei Wang, Congmin Gao, Longlong Gong
  • Patent number: 10047084
    Abstract: This application relates to imidazolone compounds, pharmaceutically acceptable salts, solvents, polymorphs or prodrugs thereof, and further relates to pharmaceutical combinations comprising the foregoing substances and uses for preventing and treating protein kinase related diseases such as cancer, metabolic diseases, and cardiovascular diseases.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: August 14, 2018
    Assignee: BEIJING FORELANDPHARMA CO. LTD.
    Inventors: Xingmin Zhang, Qi Ji, Lei Wang, Congmin Gao, Ensi Wang, Zhenjian Du, Longlong Gong, Bo Chen
  • Publication number: 20160304510
    Abstract: This application relates to imidazolone compounds, pharmaceutically acceptable salts, solvents, polymorphs or prodrugs thereof, and further relates to pharmaceutical combinations comprising the foregoing substances and uses for preventing and treating protein kinase related diseases such as cancer, metabolic diseases, and cardiovascular diseases.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 20, 2016
    Applicant: BEIJING FORELANDPHARMA CO. LTD.
    Inventors: Xingmin ZHANG, Qi JI, Lei WANG, Congmin GAO, Ensi WANG, Zhenjian DU, Longlong GONG, Bo CHEN
  • Patent number: 9315492
    Abstract: The present invention provides a heterocyclic group contained amino-methanol derivative, and salt, a preparation method and use thereof, and belongs to the medical field. The heterocyclic group contained amino-methanol derivative and the salt thereof of the present invention are used for preparing medicines for immune suppression and for the treatment of organ transplant rejection, or medicines for treating immune mediated inflammatory diseases, such as multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 19, 2016
    Assignee: Beijing Foreland Biopharma Co., Ltd.
    Inventors: Xingmin Zhang, Ensi Wang, Jing Guo, Shengxiu Niu, Zhuolin Dai, Nan Zheng, Liping Ji, Zhenfang Wang, Tie Liang
  • Publication number: 20150094337
    Abstract: The present invention provides a heterocyclic group contained amino-methanol derivative, and salt, a preparation method and use thereof, and belongs to the medical field. The heterocyclic group contained amino-methanol derivative and the salt thereof of the present invention are used for preparing medicines for immune suppression and for the treatment of organ transplant rejection, or medicines for treating immune mediated inflammatory diseases, such as multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventors: Xingmin Zhang, Ensi Wang, Jing Guo, Shengxiu Niu, Zhuolin Dai, Nan Zheng, Liping Ji, Zhenfang Wang, Tie Liang
  • Patent number: D985991
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: May 16, 2023
    Inventors: Jiangang Guo, Xingmin Zhang
  • Cup
    Patent number: D990959
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: July 4, 2023
    Inventors: Jiangang Guo, Xingmin Zhang